Rock Springs Capital Management LP recently filed their 13F report for the fourth quarter of 2022, which ended on 2022-12-31.
The 13F report details which stocks were in a guru’s equity portfolio at the end of the quarter, though investors should note that these filings are limited in scope, containing only a snapshot of long positions in U.S.-listed stocks and American depository receipts as of the quarter’s end. They are not required to include international holdings, short positions or other types of investments. Still, even this limited filing can provide valuable information.
650 South Exeter Street Baltimore, MD 21202
As of the latest 13F report, the guru’s equity portfolio contained 116 stocks valued at a total of $4.15Bil. The top holdings were HUM(5.27%), IMCR(4.57%), and PODD(3.72%).
According to GuruFocus data, these were Rock Springs Capital Management LP’s top five trades of the quarter.
Prometheus Biosciences Inc
During the quarter, Rock Springs Capital Management LP bought 386,143 shares of NAS:RXDX for a total holding of 1,031,550. The trade had a 1.03% impact on the equity portfolio. During the quarter, the stock traded for an average price of $64.84999999999999.
On 02/17/2023, Prometheus Biosciences Inc traded for a price of $123.655 per share and a market cap of $5.75Bil. The stock has returned 189.49% over the past year.
GuruFocus gives the company a financial strength rating of 6 out of 10. There is insufficient data to calculate the stock’s profitability rating.
In terms of valuation, Prometheus Biosciences Inc has a price-book ratio of 22.24, a EV-to-Ebitda ratio of -41.05 and a price-sales ratio of 688.51.
Covetrus Inc
The guru sold out of their 1,678,800-share investment in NAS:CVET. Previously, the stock had a 0.91% weight in the equity portfolio. Shares traded for an average price of $20.93 during the quarter.
On 02/17/2023, Covetrus Inc traded for a price of $20.99 per share and a market cap of $2.94Bil. The stock has returned 4.74% over the past year.
GuruFocus gives the company a financial strength rating of 4 out of 10 and a profitability rating of 5 out of 10.
In terms of valuation, Covetrus Inc has a price-book ratio of 1.95, a EV-to-Ebitda ratio of 19.71 and a price-sales ratio of 0.62.
The price-to-GF Value ratio is 1.07, earning the stock a GF Value rank of 3.
Amylyx Pharmaceuticals Inc
During the quarter, Rock Springs Capital Management LP bought 825,900 shares of NAS:AMLX for a total holding of 1,229,637. The trade had a 0.74% impact on the equity portfolio. During the quarter, the stock traded for an average price of $35.49.
On 02/17/2023, Amylyx Pharmaceuticals Inc traded for a price of $35.585 per share and a market cap of $2.36Bil. The stock has returned 53.91% over the past year.
GuruFocus gives the company a financial strength rating of 6 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, Amylyx Pharmaceuticals Inc has a price-book ratio of 14.47, a EV-to-Ebitda ratio of -11.37 and a price-sales ratio of 5946.93.
Baxter International Inc
During the quarter, Rock Springs Capital Management LP bought 394,500 shares of NYSE:BAX for a total holding of 1,150,000. The trade had a 0.48% impact on the equity portfolio. During the quarter, the stock traded for an average price of $53.71.
On 02/17/2023, Baxter International Inc traded for a price of $40.3 per share and a market cap of $20.34Bil. The stock has returned -49.88% over the past year.
GuruFocus gives the company a financial strength rating of 4 out of 10 and a profitability rating of 7 out of 10.
In terms of valuation, Baxter International Inc has a price-book ratio of 3.49, a EV-to-Ebitda ratio of -66.46 and a price-sales ratio of 1.36.
The price-to-GF Value ratio is 0.39, earning the stock a GF Value rank of 4.
ShockWave Medical Inc
Rock Springs Capital Management LP reduced their investment in NAS:SWAV by 65,000 shares. The trade had a 0.47% impact on the equity portfolio. During the quarter, the stock traded for an average price of $252.85.
On 02/17/2023, ShockWave Medical Inc traded for a price of $200.73 per share and a market cap of $7.25Bil. The stock has returned 40.58% over the past year.
GuruFocus gives the company a financial strength rating of 9 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, ShockWave Medical Inc has a price-earnings ratio of 86.15, a price-book ratio of 20.38, a EV-to-Ebitda ratio of 69.59 and a price-sales ratio of 17.07.
The price-to-GF Value ratio is 0.47, earning the stock a GF Value rank of 4.
Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.
When GuruFocus covers insider information, we only track open market or the private purchase and sale of common stock with the transaction code of P or S. Therefore, all the transactions mentioned in this article are only the ones with transaction code of P or S.
Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at [email protected]!
This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.
